[go: up one dir, main page]

Micoli et al., 2018 - Google Patents

Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends

Micoli et al., 2018

View HTML
Document ID
10185559019773921123
Author
Micoli F
Adamo R
Costantino P
Publication year
Publication venue
Molecules

External Links

Snippet

Currently licensed glycoconjugate vaccines are composed of a carbohydrate moiety covalently linked to a protein carrier. Polysaccharides are T-cell independent antigens able to directly stimulate B cells to produce antibodies. Disease burden caused by …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Similar Documents

Publication Publication Date Title
Micoli et al. Protein carriers for glycoconjugate vaccines: history, selection criteria, characterization and new trends
Micoli et al. GMMA is a versatile platform to design effective multivalent combination vaccines
Nishat et al. Entirely carbohydrate-based vaccines: an emerging field for specific and selective immune responses
Lagousi et al. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens
Pizza et al. Vaccines against meningococcal diseases
Bitto et al. The therapeutic benefit of bacterial membrane vesicles
McCarthy et al. Meningococcal vaccines: current status and emerging strategies
Di Benedetto et al. Rational design of a glycoconjugate vaccine against Group A Streptococcus
Li et al. Recent advances in toll like receptor-targeting glycoconjugate vaccines
Raso et al. GMMA and Glycoconjugate Approaches Compared in Mice for the Development of a Vaccine against Shigella flexneri Serotype 6
MacCalman et al. Glycoconjugate vaccines: some observations on carrier and production methods
van der Put et al. Carriers and antigens: new developments in glycoconjugate vaccines
Micoli et al. Towards a four-component GMMA-based vaccine against Shigella
Romano et al. Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity
Martin et al. The ongoing journey of a Shigella bioconjugate vaccine
Kalfopoulou et al. Advances and prospects in vaccine development against enterococci
Tamborrini et al. A synthetic virus-like particle streptococcal vaccine candidate using B-cell epitopes from the proline-rich region of pneumococcal surface protein A
Baliban et al. Immunogenicity and induction of functional antibodies in rabbits immunized with a trivalent typhoid-invasive nontyphoidal Salmonella glycoconjugate formulation
Jha et al. Complementary role of CD4+ T cells in response to pneumococcal polysaccharide vaccines in humans
Phalipon et al. Toward a multivalent synthetic oligosaccharide-based conjugate vaccine against Shigella: state-of-the-art for a monovalent prototype and challenges
Morais et al. Conjugation mechanism for pneumococcal glycoconjugate vaccines: classic and emerging methods
Di Benedetto et al. Novel simple conjugation chemistries for decoration of GMMA with heterologous antigens
Bundle et al. A three component synthetic vaccine containing a β-mannan T-cell peptide epitope and a β-glucan dendritic cell ligand
Palmieri et al. Stability of outer membrane vesicles-based vaccines, identifying the most appropriate methods to detect changes in vaccine potency
Bayart et al. Tetanus toxin fragment C: structure, drug discovery research and production